The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD [0.03%]
肝硬化无创评估的明路（EPoS）分期系统：MASLD纤维化分级评分系统的可重复性及7级评分标准
Dina G Tiniakos,Pierre Bedossa,Johanna Arola et al.
Dina G Tiniakos et al.
Background & aims: Fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) is histologically staged using the 5-tiered NASH CRN system, which has limited resolution for advanced fibrosis stages that a...
CAR-T cells targeting activated hepatic stellate cells ameliorate liver fibrosis in mouse models [0.03%]
针对活化肝星状细胞的CAR-T细胞可改善小鼠模型肝纤维化
Yang-Wen-Qing Zhang,Hui Ren,Minghe Zhang et al.
Yang-Wen-Qing Zhang et al.
Background & aims: The transition to liver fibrosis represents a crucial and irreversible transition in chronic liver diseases, with liver fibrosis being a key driver of the progression to life-threatening complications, ...
The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression [0.03%]
KLB基因rs12152703变异通过提高β衰老化因子表达来预防代谢相关脂肪性肝病患者的肝脏炎症
Marica Meroni,Nadia Panera,Erika Paolini et al.
Marica Meroni et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide, paralleling the rising prevalence of obesity. We previously reported that th...
Long-term outcomes and temporal trends following liver transplantation for chronic liver disease in the intensive care unit [0.03%]
重症监护病房慢性肝病患者肝脏移植的长期预后及近期趋势分析
Magdalena Meszaros,José Ursic-Bedoya,Audrey Coilly et al.
Magdalena Meszaros et al.
Background & aims: Liver transplantation (LT) remains the definitive treatment for patients with end-stage chronic liver disease (CLD). However, those transplanted while in the intensive care unit (ICU) represent a high-r...
Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach [0.03%]
基于转录组和基因组的方法确定肝细胞癌患者的索拉非尼治疗获益者
Sun Young Yim,Hayeon Kim,Tae Hyung Kim et al.
Sun Young Yim et al.
Background & aims: Sorafenib has been a cornerstone of hepatocellular carcinoma (HCC) therapy; however, its efficacy is limited, and identifying patients who will benefit from sorafenib is challenging. We aimed to identif...
Spatial transcriptional profiling of CHB liver biopsies reveals an undetected population of zonally biased HBV-integrated cells [0.03%]
空间转录组揭示慢性乙型肝炎患者肝脏活检标本中HBV整合病毒的区域分布特征及其在静息细胞中的潜伏状态
Sangeetha Mahadevan,Ricardo Ramirez,Hatef Mehrabian et al.
Sangeetha Mahadevan et al.
Background & aims: HBV covalently closed circular DNA (cccDNA) and HBV-integrated DNA (iDNA) are features of chronic HBV (CHB). Elimination of both cell populations is likely to be required for functional cure. RNA-based ...
Cyrielle Caussy,Sven M Francque
Cyrielle Caussy
Obesity has emerged as a major global health challenge and is closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction- and alcohol-associated liver disease (MetALD). Overall, an inc...
Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways [0.03%]
糖尿病和肥胖会降低FIB-4在代谢相关脂肪性肝病转诊途径中的准确性
Abdel-Aziz Shaheen,Elizabeth Baguley,Mark G Swain et al.
Abdel-Aziz Shaheen et al.
Background & aims: Primary care referral pathways often use FIB-4 to triage metabolic dysfunction-associated steatotic liver disease (MASLD), but its accuracy may vary by patient characteristics. We aimed to evaluate FIB-...
Brandon Lok-Hang Chan,Yan Li,YoungJae Kim et al.
Brandon Lok-Hang Chan et al.
Background & aims: Intrahepatic cholangiocarcinoma (ICC) with multiple liver tumours is staged as T2 disease in the 8th edition of the AJCC staging system. However, tumour multiplicity is frequently associated with poor p...
Reply to: "Gene-environment "amplification" of liver stiffness requires more clinically meaningful analytic approaches" [0.03%]
肝硬度的基因-环境放大效应需要更有临床意义的分析方法答复文章
Sophie Gensluckner,Helle Lindholm Schnefeld,Maja Thiele et al.
Sophie Gensluckner et al.